Increased EGFR/HER2 Pathway Activation Contributes to Skin Tumorigenesis in Tpl2−/− Mice
Authors:
- Laura R. PurkeyLPLaura R. Purkey
- Stefania MehedincuSMStefania Mehedincu
- Charles IrvineCICharles Irvine
- Raelyn AkdagRARaelyn Akdag
- Megan LittleMLMegan Little
- W. Wade KothmannWKW. Wade Kothmann
- Katharine RusKRKatharine Rus
- Erin GreenbergEGErin Greenberg
- Neil ShadyNSNeil Shady
- Kathleen DeCicco-SkinnerKDKathleen DeCicco-Skinner
Open Access
Abstract
Background: The mitogen-activated protein kinase (MAPK) signaling pathway is frequently dysregulated in cutaneous squamous cell carcinoma (cSCC). Tumor progression locus 2 (Tpl2), a serine/threonine protein kinase within the MAPK family, regulates cellular proliferation, survival, and inflammatory responses. Loss of Tpl2 activates compensatory signaling cascades, driving increased papilloma and cSCC development. In this study we examined whether dysregulated ErbB signaling contributes to the enhanced tumor burden found in Tpl2−/− mice. Methods: To evaluate whether aberrant ErbB signaling drives tumorigenesis in Tpl2−/− mice, wild-type (Tpl2+/+) and Tpl2−/− mice were subjected to a two-stage chemical carcinogenesis protocol for 48 weeks. A subset of mice received Gefitinib (an EGFR inhibitor) or Lapatinib (a HER2 inhibitor) in their diet. Results: We found that Tpl2 ablation increases gene expression of EGFR, HER2, and HER3, while baseline protein levels remain unchanged between Tpl2 genotypes. To investigate the possibility of microRNA (miR)-mediated post-transcriptional regulation of EGFR, HER2, and HER3, we measured ErbB-related miR expression in keratinocytes. We found that HER2/3-related miRs 205 and 21 are increased in Tpl2−/− keratinocytes. Further, Tpl2 loss enhances p-EGFR, EGFR, and HER2 protein expression in papillomas. and HER2-related microRNAs (miRs) 205 and 21 in keratinocytes, and enhances p-EGFR, EGFR, and HER2 protein expression in papillomas. Tpl2−/− mice developed 12-fold more papillomas and 4-fold more cSCCs compared to Tpl2+/+ animals. Treatment with Gefitinib or Lapatinib reduced papilloma numbers by 88% and 50%, respectively, while restoring cSCC numbers to Tpl2+/+ levels. Conclusions: These findings indicate that ErbB targeting represents a promising therapeutic strategy for cSCCs arising from MAPK pathway dysregulation.Keywords
Funding Information
- Mellon funding
This publication has 34 references indexed in Scilit:
- Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinomaiScience, 2023
- The landscape of driver mutations in cutaneous squamous cell carcinomanpj Genomic Medicine, 2021
- The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990–2017JAAD International, 2021
- Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancerOncogenesis, 2019
- The microRNA landscape of cutaneous squamous cell carcinomaDrug Discovery Today, 2018
- ERBB2 Is Essential for the Growth of Chemically Induced Skin Tumors in MiceJournal of Investigative Dermatology, 2017
- MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomasArchives of Dermatological Research, 2016
- Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinaseCell Research, 2010
- Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesisOncogene, 2010
- Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient miceNature Protocols, 2008